Cancer
IBM tests cancer diagnostic
October 24, 2013Medical Communications, Research and Development, Sales and Marketing Cancer, Zurich, ibm
IT giant IBM has teamed up with the University Hospital in Zurich to research a new oncology diagnostic test, in …
AZ begins late-stage trial of new cancer drug
October 22, 2013Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib
AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …
The new paradigm in oncology drug marketing
October 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Herceptin, Roche, marketing, oncology
Twenty years ago drugs to treat cancer were made up of chemotherapy agents which are essentially ‘blunt tools’ against the …
Roche rules out merger talk
October 18, 2013Sales and Marketing Cancer, Herceptin, Novartis, Roche, merger
Roche has dismissed talk of merging with fellow Swiss manufacturer Novartis as it revealed its results for the last three …
Astellas gets NICE nod
October 18, 2013Sales and Marketing Cancer, NHS, NICE, Xtandi
Astellas Pharma’s new prostate cancer drug Xtandi which has been shown to shrink and kill cancer cells, has been recommended …
AstraZeneca pays $460m for cancer specialists
October 15, 2013Research and Development, Sales and Marketing ADC, AstraZeneca, Cancer, MedImmune, spirogen
AstraZeneca’s biologics arm MedImmune has bought cancer biotech firm Spirogen and set up a licensing deal with ADC Therapeutics for …
Billions spent on European cancer care
October 15, 2013Research and Development, Sales and Marketing Cancer, Europe, Lancet, Oxford, Pfizer
A new report has shown that cancer cost the European Union a total of €126 billion in 2009, with healthcare …
Calls to end UK anti-vaccine magazine
October 2, 2013Medical Communications, Sales and Marketing Cancer, Vaccine, sense about science
British retailers like Tesco and WH Smiths are being urged to drop an anti-vaccine magazine as it could be dangerous …
Cancer survival rates linked to government spending in EU
October 1, 2013Research and Development, Sales and Marketing CDF, Cancer, EU, NICE
The bigger an EU country’s healthcare budget, the greater its cancer patients’ prospects of survival, according to new research released …
CHMP recommends cancer ‘smart bomb’
September 23, 2013Research and Development, Sales and Marketing CHMP, Cancer, EMA, Kadcyla, Roche
Teva in Cancer Research UK tie-up
September 20, 2013Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer, R&D, Teva
Bayer partners with US academics
September 13, 2013Research and Development, Sales and Marketing Bayer, Cancer, broad, oncology
Bayer HealthCare and a prestigious US academic institution have signed a five-year deal to find new oncology treatments. The German …
AstraZeneca pays Merck for cancer drug
September 11, 2013Sales and Marketing AstraZeneca, Cancer, Merck, WEE1
AstraZeneca is to pay $50 million up front to get a worldwide licensing deal for one of Merck’s investigational drugs …
‘Inequality’ for Welsh cancer patients
August 28, 2013Sales and Marketing CDF, Cancer, England, NHS, NICE, Wales
Cancer sufferers in England are four times more likely to receive newer treatments on the NHS than patients in Wales, …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
